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The7theditionoftheAJCCCancerStagingManualrepresentsadramaticshiftinthewaythatcutaneoussquamouscellcarcinoma
(cSCC) is staged, in that it is ﬁrst attempt to incorporate evidence-based medicine into the staging guidelines for cSCC. In our
opinion, the changes made to the seventh edition represent a signiﬁcant improvement over previous editions and will ultimately
lead to improved patient stratiﬁcation, more accurate prognostic data, and a better framework to guide clinical decision making.
However, there are a number of issues within the latest guidelines that require clariﬁcation or are impractical for clinical practice.
The purpose of this paper is to highlight the key changes to the 6th edition staging manual as they pertain to cSCC, to point
out impractical component of the 7th edition and/or aspects that require further clariﬁcation, and to make recommendations
that address any current shortcomings to improve subsequent editions. Speciﬁc focus will be given to the inclusion of separate
guidelines for cSCC and Merkel cell carcinoma (MCC), the incorporation of high-risk factors as modiﬁers of T stage, the addition
of new guidelines for advanced T stage, and the changes in stratiﬁcation of lymph node status. This paper is modiﬁed from a
more comprehensive treatment of the staging of nonmelanoma skin cancer by Warner and Cockerell entitled “The new 7th edition
American joint committee on cancer staging of cutaneous nonmelanoma skin cancer: a critical review,” in the American Journal of
Clinical Dermatology (paper accepted, pending publication).
1.Introduction
TheseventheditionoftheAJCCCancerStagingManualrep-
resents a dramatic shift in the way that cutaneous squamous
cell carcinoma (cSCC) is staged, in that it is the ﬁrst attempt
to incorporate evidence-based medicine into the staging
guidelines for cSCC. In our opinion, although the changes
represent a signiﬁcant improvement over previous editions
and will likely lead to improved patient stratiﬁcation, more
accurate prognostic data and a better framework to guide
clinical decision making, there are a number of issues that
require clariﬁcation and that are impractical for clinical
practice. The purpose of this paper is to highlight the key
changes to the 6th edition staging manual as they pertain
to cSCC, to point out impractical components of the 7th
edition and/or aspects that require further clariﬁcation, and
to make recommendations that address any current short-
comings to improve subsequent editions. Speciﬁc focus will
be given to the inclusion of separate guidelines for cSCC and
Merkelcellcarcinoma(MCC),theincorporationofhigh-risk
factors as modiﬁers of T stage, the addition of new guidelines
for advanced T stage, and the changes in stratiﬁcation of
l y m p hn o d es t a t u s[ 1]. This paper is modiﬁed from a more
comprehensive treatment of the staging of nonmelanoma
skin cancer by Warner and Cockerell entitled “The new
7th edition american joint committee on cancer staging of
cutaneous nonmelanoma skin cancer: a critical review,” in the
American Journal of Clinical Dermatology (paper accepted,
pending publication) [2].
New Changes to 6th Edition (see Table 1).2 Journal of Skin Cancer
Table 1: AJCC cancer staging manual summary of changes from the sixth edition to the seventh edition.
(i) The chapter entitled “Carcinoma of the Skin,” has been eliminated and two chapters have been created in its place:
(ii) “Merkel Cell Carcinoma”: an entirely new chapter speciﬁcally for Merkel cell carcinoma (MCC) has been designed (see Chapter 30).
(iii) This chapter has been renamed “Cutaneous Squamous Cell Carcinoma and Other Cutaneous Carcinomas” and is an entirely new
staging system that, for the ﬁrst time, reﬂects a multidisciplinary eﬀort to provide a mechanism for staging nonmelanoma skin cancers
according to evidence-based medicine. The title of this chapter reﬂects the basis of the data, which is focused on cutaneous squamous cell
carcinoma (cSCC). All other nonmelanoma skin carcinomas (except Merkel cell carcinoma) are also to be staged according to the cSCC
system.
(iv) Anatomic site of the eyelid is excluded—cSCC of the eyelid are staged by ophthalmic carcinoma of the eyelid (see Chapter 48).
Cutaneous SCC of the penis, vulva, and mucosal lip are also excluded, as they are staged with chapters speciﬁc for those anatomic sites.
(v) The T staging has eliminated the ﬁve-centimeter-size breakpoint and invasion of extradermal structures for T4. Two centimeters
continues to diﬀerentiate T1 and 2; however, a list of clinical and histologic “high-risk features” have been created that can increase the T
staging, independent of tumor size.
(vi) Grade has been included as one of the “high-risk features” within the T category and now contributes toward the ﬁnal stage grouping.
Other “high-risk features” include primary anatomic site of ear or hair-bearing lip, invasion greater than two millimeters depth, Clark’s
level greater than or equal to IV, or perineural invasion.
(vii) Advanced T stage is reserved for invasion of speciﬁc anatomic sites (maxilla, mandible, orbit, or temporal bone involvement for T3;
appendicular or axial skeletal involvement or perineural invasion of the skull base for T4).
(viii) Nodal (N) staging has been completely revised to reﬂect published evidence-based data demonstrating that survival decreases with
increasing nodal size and number of nodes involved.
(ix) Because the majority of cSCC tumors occur on the head and neck, the seventh edition staging system for cSCC and other cutaneous
carcinomas was made congruent with the AJCC head and neck staging system.
From the AJCC 7th edition “Cutaneous Squamous Cell Carcinoma and Other Cutaneous Carcinomas”.
2. Creation of Separate Guidelines for
CutaneousSquamousCellCarcinomaand
Merkel Cell Carcinoma
One of the most dramatic changes to the AJCC 6th edition
is the creation of separate staging guidelines for cSCC and
Merkel cell carcinoma. In previous versions, these two can-
cers were grouped together, along with 80 other cutaneous
neoplasms, under a single chapter entitled “Carcinoma of
the Skin” [3, 4]. This chapter has been eliminated with the
7th edition and replaced by 2 separate chapters: “Merkel
Cell Carcinoma” and “Cutaneous Squamous Cell Carcinoma
and Other Cutaneous Skin Cancers.” Under this format, all
Nonmelanoma, non-Merkel cell skin cancers are to be staged
under the cSCC staging system [1].
The creation of separate guidelines represents a signif-
icant improvement over previous editions, as cSCC and
Merkel cell carcinoma exhibit markedly diﬀerent behavior.
In general, cSCC portends a much more favorable prognosis,
with a cure rate greater than 90%, and a disease-speciﬁc
yearly mortality rate of approximately 1% per year in
the U.S [5, 6]. Additionally, the ﬁve year recurrence and
metastatic rates for cSCC are 8% and 5%, respectively [5,
7, 8]. In contrast, MCC tends to be much more aggressive,
with an overall disease-speciﬁc survival rate of 76% and
overall recurrence and metastatic rates of 52% and 31%,
respectively [9–11]. Compared to cSCC, MCC tends to
exhibit lymphatic spread earlier in the disease course, as
up to 14% of patients present with palpable lymph nodes
in the absence of an identiﬁable primary tumor [12], and
nearly a third of patients without clinically evident lymph
nodes have evidence of lymphatic spread on sentinel lymph
node biopsy [13]. Similarly, while histologic grade, depth
of invasion, and perineural involvement have been shown
to have important prognostic features for cSCC [5, 14], a
signiﬁcant association has not been demonstrated for MCC
[15, 16].
Given the signiﬁcant diﬀerences in clinical behavior,
application of a single set of guidelines to both cSCC and
MCC can be problematic. Guidelines tailored towards MCC
may lead to upstaging of cSCC lesions, placing an unnec-
essary emotional burden on patients and exposing them
to signiﬁcantly morbid treatments they may not require.
Conversely, guidelines designed for cSCC may understage
MCC patients, preventing them from receiving the more
aggressive therapy they require. In particular, there is some
evidence that understaging of MCC lesions may have been a
problem with the 6th edition guidelines [16].
However, this shortcoming is largely rectiﬁed in the
7th edition AJCC staging manual through the creation of
separatestagingguidelinesorientedtowardscSCCandMCC,
respectively. The chapter entitled “Merkel Cell Carcinoma”
is speciﬁc to MCC, leading to greater applicability and
accuracy of guidelines for patients with this disease. As its
name implies, the chapter entitled “Cutaneous Squamous
Cell Carcinoma and other Cutaneous Skin Cancers” is
primarily oriented towards cSCC. These changes highlight
a shift towards the creation of more cancer speciﬁc staging
guidelines, improving their ability to assess prognosis and
guide treatment decisions.
While these changes represent a signiﬁcant improvement
over previous editions, they also highlight an important
issue that still remains. Despite a greater focus on cSCC, the
AJCC staging manual still groups all Nonmelanoma, non-
Merkel cell skin cancers, a diverse set of over 80 diﬀerent
types of tumors, under a single set of staging guidelinesJournal of Skin Cancer 3
[1, 3]. As a result, the applicability of these guidelines to
any individual cancer is impaired. Pertaining to cSCC, there
is signiﬁcant variation regarding clinical behavior amongst
diﬀerent variants/subtypes. This leads to several instances
wheretheapplicationoftheguidelinesmaybeinappropriate,
particularly for less aggressive variants. Although locally
aggressive, the verrucous form of cSCC tends to exhibit
a less aggressive clinical course than other subtypes and
rarely metastasizes [2]. Similarly, keratoacanthomas exhibit
predominantly benign clinical behavior, and usually only
require conservative treatment for cure [2, 17]. Given their
relatively benign behavior, staging these lesions using the
7th edition guidelines creates the undesirable situation
whereby a patient may be inappropriately upstaged and
assigned an unnecessarily high risk. Finally, although it
seems unlikely that the authors of the cSCC staging chapter
intend for all other cutaneous neoplasms, including basal
cell carcinomas which tend not to metastasize, as well as
many tumors which behave in an essentially benign fashion,
such as adnexal tumors, to receive full pathologic staging
evaluation, the authors did not explicitly state this. We feel
that for clariﬁcation, the authors should make some formal
acknowledgment that many other cutaneous tumors do not
require the full assessment needed for cSCC.
3. New Guidelinesfor PrimaryTumor (T)
Stage Assessment
The primary tumor (T) designation of the TNM staging
system has been signiﬁcantly revised in the 7th edition
(Table 2). While the 2cm size cutoﬀ still distinguishes T1
and T2 lesions, high risk features capable of upstaging a
T1 lesion to T2 have been incorporated for the ﬁrst time.
The speciﬁc high-risk features included are depth of invasion
(>2mm, ≥Clark level IV), perineural invasion, tumor grade
(poorly diﬀerentiated or undiﬀerentiated), and presence on
high-risk anatomic sites (the lip and ear). In addition, the
previous advanced T stage requirements (>5cm for T3;
presence of extradermal invasion for T4) have been replaced
by involvement of speciﬁc anatomic locations (the maxilla,
mandible, orbit, and temporal bone for T3 lesions, and
axial or appendicular skeletal involvement or perineural
involvement of the skull base for T4 lesions).
4. Addition of High-Risk Factors as
Modiﬁers of T Stage
4.1. Histologic Diﬀerentiation. One of the high-risk features
included in the 7th edition of the AJCC staging manual
is the presence of poorly diﬀerentiated or undiﬀerentiated
histology.Thisisbasedonseveralstudieswhichhavedemon-
strated the relationship between high-grade (Broders class 3
and 4) and aggressive clinical behavior [5, 18]. Compared to
well-diﬀerentiated tumors, poorly diﬀerentiated neoplasms
have been shown to exhibit twice the local recurrence rate
and three times the metastatic rate [5]. Additionally, Rowe et
al.demonstratedasigniﬁcantrelationshipbetweenmortality
andtumorgrade[5],astheﬁve-yearcurerateaftertreatment
Table 2: Primary tumor (T)∗.
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Carcinoma less than 2cm in greatest dimension, with
less than 2 high risk features∗∗
T2
Carcinoma greater than 2cm in greatest dimension,
Or Tumor of any size with at least 2 high risk
features∗∗
T3 Tumor invasion of the maxilla, mandible, orbit, or
temporal bone
T4 Tumor invasion of the skeleton (appendicular or axial)
or with perineural involvement of the skull base
∗Excludes cutaneous SCC of the eyelid.
∗∗High-risk features for the primary tumor (T) staging:
Depth/invasion: >2mm thickness, Clark level ≥IV, Perineural invasion.
Anatomic location: Primary site ear, Primary site non-hair-bearing lip.
Diﬀerentiation: Poorly diﬀerentiated or undiﬀerentiated.
From the AJCC 7th edition “Cutaneous Squamous Cell Carcinoma and
Other Cutaneous Carcinomas”.
was 61.5% for poorly diﬀerentiated cSCC, compared to
94.6% for patients with well-diﬀerentiated cSCC.
Although we feel that incorporation of tumor grade in
the staging guidelines represents a signiﬁcant improvement
over earlier editions, we ﬁnd the current description prob-
lematic, as it lacks signiﬁcant details and omits several his-
tologic features associated with high risk-disease. According
to the AJCC, “high-grade tumors show poor diﬀerentiation,
spindle cell characteristics, necrosis, high mitotic activity,
a n dd e e pi n v a s i o n ”[ 1]. As noted by Warner and Cockerell,
the description also omits several features of high-risk cSCC
variants. Speciﬁcally, there is no mention of acantholytic
SCC, SCC with basaloid features, SCC with a sclerosing
pattern, “carcinosarcoma,” or basosquamous morphology
[2]. Also absent from this description is the presence of lym-
phovascular invasion or inﬂammatory response. Although
less well established than other features, there is evidence
that lymphatic or vascular invasion is strongly associated
with metastatic disease [18, 19]. Similarly, the presence of an
inﬂammatory response typiﬁed by eosinophils and plasma
cells has been shown to be predictive of metastases [18].
Although high mitotic activity is mentioned as a charac-
teristic of high-grade neoplasms, there is no description of
the number of mitoses required to qualify as such, nor is
there any description of atypical mitoses [2]. Moreover, there
is no description regarding what percentage of a neoplasm
must display these features in order to be deﬁned as “poorly
diﬀerentiated” or “undiﬀerentiated” [2]. Overall, we ﬁnd
the current description of histologic features of high-grade
lesions signiﬁcantly lacking, which limits its application in
clinical practice [2].
4.2. Depth of Invasion/Perineural Invasion. Based on current
research, depth of invasion may be the most important
tumor variable associated with prognosis [18–23]. In a study
by Rowe et al. [5], the presence of either tumor thickness4 Journal of Skin Cancer
>4mm or depth of invasion ≥Clark level IV was associated
withanincreasedrateofrecurrencebyafactorof2,aswellas
anincreaseintherateofmetastasisbyafactorof5.Similarto
melanoma, there is evidence that Breslow thickness is more
important for determining prognosis in cSCC than Clark’s
level, although both are predictive of advanced disease [22].
Additionally, while early studies identiﬁed Breslow thickness
>4mm as predictive of aggressive behavior [5], subsequent
studies have shown that a 2mm cutoﬀ more appropriately
stratiﬁes low and high risk lesions [18].
Perineural invasion has also been found to be a signiﬁ-
cant indicator of high-risk disease [5, 24–28]. Although less
commonly identiﬁed (only present in 5 percent of cSCCs)
[26, 27], there is some evidence that perineural invasion is
associated with an increase in both the recurrence rate and
the metastatic rate by a factor of 5 [29]. As perineural spread
can be diﬃcult to follow histologically and clinically, tumors
can spread to great extent prior to detection [26, 27]. In
general, the identiﬁcation of perineural invasion carries a
dismal prognosis, as the 5-year mortality rate approaches
90% [29].
Given the wealth of epidemiologic data, the authors
of the 7th edition chose to include advanced tumor
depth/invasion (deﬁned as >2mm in thickness, ≥Clark level
IV) among the high-risk features capable of upstaging a
T1 neoplasm. Overall, this represents an improvement over
previouseditions,asitallowsfortheidentiﬁcationofasubset
of lesions that, although small in size, nevertheless are likely
to demonstrate aggressive clinical behavior.
However, the incorporation of these factors may be
impractical for widespread use in clinical practice. As the
manual does not include any exceptions to the updated stag-
ing criteria (aside from the anatomic location on vermillion
or mucosal lip, eyelid, penis, or vulva, as cSCC on these sites
are staged with the chapters for these anatomic locations), it
implies that this data should be recorded for each and every
cSCC. In particular, the accurate assessment of Breslow-
type thickness requires the use of an optical micrometer and
represents a signiﬁcant investment of physician time and
labor [2]. While in some cases performing such a thorough
assessment is beneﬁcial, for small or low-risk lesions, such
thorough histopathologic staging could be viewed as a waste
of valuable physician resources [2]. This is compounded by
the large number of cases of cSCC, estimated to be greater
than700,000peryearintheUS[30],withmostofthesebeing
low-risk lesions [29]. In our opinion, very small cutaneous
SCCs removed completely with initial biopsy from low-risk
anatomic sites do not warrant full clinicopathologic staging
evaluation and should be excluded from the new staging
requirements [2]. Similarly, for verrucous variants of SCC,
which may exhibit locally aggressive behavior but rarely
metastasizes, full evaluation is unnecessary, and as such, it
too should be included as an exception [2].
In situations where histopathologic staging is warranted,
there are additional concerns regarding evaluation of tumor
depth. In particular, for many initial biopsies, accurate
assessment of depth is impossible, as the tumor boundary
extends beyond the base of the specimen [2]. Similarly,
most biopsies of large tumors are taken in parte at the
tumor edge, precluding initial assessment of the full depth
of tumor invasion. If reexcision is performed by Mohs
surgeons, the debulk specimen will frequently not be sent
for H&E processing. In order to obtain accurate staging
information, dermatologic surgeons will need to be trained
to obtain accurate assessment of vertical depth of invasion of
the debulk specimen. Another concern is that many biopsy
methods do not adequately maintain tissue architecture,
such as shave or curettage techniques [2]. In these cases,
accurate assessment of depth of invasion is not possible, even
though in some of these instances, the tumor may have been
already completely removed with the initial procedure.
4.3. High-Risk Anatomic Sites. The ﬁnal high-risk feature
identiﬁed in the 7th edition guidelines is the location of
the primary tumor on high-risk anatomic sites. This is
based on evidence that lesions located on the lip and ear
are more aggressive compared to tumors present on other
locations throughout the body. Based on epidemiologic data,
these anatomic sites are associated with recurrence and
metastatic rates between 10 to 25 percent [5, 31]. Similar
to the previously mentioned high-risk variants, recognition
of the increased risk associated with these sites improves
the prognostic information provided by the 7th edition
guidelines.
Despite this, there are speciﬁc problems worth noting
regarding 7th edition’s current description of high-risk
anatomicsites.AsdescribedbyWarnerandCockerell[2],the
speciﬁcanatomicdescriptionsofthelipasahigh-risksiteare
confusing and seemingly contradictory. For clariﬁcation, we
are accustomed to the lip being divided into three separate
anatomic regions: (1) cutaneous (hair-bearing or glabrous)
lip; (2) vermillion lip (the sun exposed portion of the lip
extending from the vermillion border to the line created by
the opposed lips when the mouth is closed), and (3) mucosal
lip (commonly referred to as the wet portion of the lip, it
extends from the vermillion border posteriorly into the oral
cavity) [32, 33]. Within the cutaneous carcinoma chapter of
the AJCC manual, “hair-bearing lip” (an apparent reference
to cutaneous lip) is deﬁned as a high-risk anatomic site
capable of upstaging a T1 neoplasm. However, a summary
table within the same chapter (on page 307) refers to “non-
hair-bearing lip” as the site associated with increased risk
[1], a description that would seem to indicate vermillion lip.
Complicating the matter further is the anatomic description
of mucosal lip within the chapter on cancers of the oral
cavity, which is deﬁned as “...begin[ning] at the junction
of the vermillion border with the skin and includes only
the vermillion surface or that portion of the lip that comes
into contact with the opposing lip” [1]. This description
would seem to indicate that the region traditionally ascribed
as vermillion lip should be staged along with cancers of
the oral cavity, as was the case with the 6th edition [3].
Part of the source of confusion is that the vermillion outer
lip and the mucosal inner lip are both lined by squamous
mucosa, although the former is dry and the latter is wet
mucosa. Given these confusing and seemingly contradictory
statements, greater clarity is needed prior to widespread
clinical adoption of these guidelines [2].Journal of Skin Cancer 5
If tumors arising on the vermillion lip are to be staged
with cancers of the oral cavity, as they were in the 6th
edition [3], we ﬁnd this grouping problematic [2]. SCC on
the sun exposed portions of the lip, similar to cSCC, is
most commonly associated with sun exposure, with total
cumulative sun exposure being the most signiﬁcant risk
factor [31]. However, SCC originating in the oral cavity is
primarily associated with alcohol or tobacco use, chronic
inﬂammation, or HPV infection [34, 35]. As argued by
Warner and Cockerell, due to the diﬀerences in etiology,
these cancers may exhibit signiﬁcantly diﬀerent clinical
behavior, making their common grouping inappropriate [2].
Another limitation of the high-risk anatomic site desig-
nation is the omission of several locations associated with
increased risk of recurrence or metastasis. While many high-
riskareasareaccountedforunderseparatestagingguidelines
(vermillion and mucosal lip, eyelid, penis, and vulva), a
number of additional sites are currently unaccounted for.
In particular, the central face, periorbital nose, chin, pre-
and postauricular sulci, temple, mandible, scalp, temple, and
dorsal hands and feet have all been associated with increased
risk [27, 28, 36]. By failing to recognize the risk associated
with these sites, the current guidelines may understage a
subset of lesions with a propensity for more aggressive
clinical behavior. We do recognize that being overly inclusive
with regards to high-risk sites could be problematic, as the
associated risk is not uniform across all locations. However,
we agree with Warner and Cockerell that the central face
and dorsal hands and feet warrant strong consideration for
subsequent editions [2].
4.4. Pertinent High-Risk Factors Omitted in the 7th Edition.
While the inclusion of selected high-risk features represents
a signiﬁcant improvement over previous editions, several
other variables associated with aggressive tumor behavior
were omitted and bear mention, including the presence of
immunosupression, occurrence of cSCC at sites of prior
chronic inﬂammation/burn/scar, and recurrence of previ-
ously treated tumors.
One of the most important risk factors associated
with cSCC is host immune status. Numerous studies have
displayed the signiﬁcant impact immunosuppression has
on both the incidence and biologic characteristics of cSCC
[5, 37, 38]. cSCC tumors in immunosuppressed patients
exhibit a strong propensity to recur and metastasize and
frequently exhibit aggressive behavior irrespective of size
[37, 38]. While the authors of the 7th edition acknowledge
the impact immune status has on prognosis, they chose
not to include it, as TNM staging is focused primarily
on tumor characteristics rather than host factors. Rather,
they recommend institutions wishing to record immune
status data include an “I” qualiﬁer in the ﬁnal stage to
denote immunosuppression [1]. Although we understand
the authors’ concerns regarding the inclusion of patient
characteristics into a staging protocol focused on tumor-
speciﬁc variables, we feel that they should have taken a more
aggressive stance regarding documentation of immunosup-
pression. We feel that a system whereby immune status
data is recorded in all cases, using an “IS” designation for
immunosuppression and “IC” for immunocompetent would
dramatically improve the epidemiologic data available by
helping elucidate the role immune status plays regarding
clinical behavior and prognosis [2]. Moreover, by not
including this high-risk variable, the current system misses
a subset of patients who, despite having tumors small in size,
are likely to experience an aggressive clinical course [38].
cSCC that arise within scars, sinus tracts, burns, or in the
settingofachronicinﬂammationhavebeenshowntoexhibit
more aggressive clinical behavior and a greater propensity
to metastasize [5, 39, 40]. The short-term metastatic rate
for these lesions is roughly 25 percent, while the overall
metastatic rate approaches 40 percent [5]. Although these
lesions are very rare, representing less than 1% of metastatic
lesions [5], given the signiﬁcant risk associated with them,
we agree with Warner and Cockerell that the AJCC should
give strong consideration to including these lesions among
the high-risk factors capable of upstaging a small neoplasm
[2].
Recurrent disease is an additional factor worth noting.
The presence of recurrent or persistent disease is a strong
prognosticvariableformetastasisandcontroloflocaldisease
[5, 41]. Recurrent or previously treated tumors tend to be
more aggressive, less responsive to treatment, and associated
with decreased survival (78% 5-year survival compared to
97% for primary lesions) [42]. Although rarely performed
for cutaneous SCC, under the current TNM staging system,
recurrent neoplasms are denoted with an “r” qualiﬁer prior
to TNM-speciﬁc designations (for example, rT2N0M0 for a
locally recurrent tumor greater than 2cm in size, without
evidence of lymph node involvement or metastasis) [1, 39].
As a result, a subset of high-risk lesions are clearly deﬁned
as such, and data collection for these tumors is signiﬁcantly
enhanced. However, in light of most recent changes to T
staging criteria, a recurrent neoplasm less than 2cm with
only 1 of the three high-risk features would be classiﬁed
as a Stage I neoplasm rather than Stage II, despite its less
favorable prognosis. Given this, we feel that recurrent or
previously treated neoplasms should be included among
the high-risk features capable of upstaging a neoplasm.
Importantly, we do not recommend altering the current
“r” qualiﬁer, as this designation helps facilitate improved
epidemiologic data.
5. Changes inAdvanced T Stage Designation
In the 7th edition staging manual, T3 tumors are now
classiﬁed as those with bony extension to the mandible,
maxilla, temple, or orbit whereas the T4 designation is
reserved for perineural involvement of the skull base or
bony extension to the axial or appendicular skeleton. More
practical than previous versions, these speciﬁc designations
representanattempttoachievegreatercongruencewithhead
and neck cancer guidelines [3].
A drawback to the new guidelines pertaining to advanced
T stage is the inclusion of appendicular skeletal involvement
with T4 lesions. It seems inappropriate to assign the same6 Journal of Skin Cancer
Table 3: Regional lymph nodes (N).
Nx Regional lymph nodes cannot be assessed.
N0 No regional lymph node metastases.
N1 Metastasis in a single ipsilateral lymph node, 3cm or
less in greatest dimension.
N2
Metastasis in a single ipsilateral lymph node, more
than 3cm but not more than 6cm in greatest
dimension; or in multiple ipsilateral lymphnodes,
none more than 6cm in greatest dimension; or in
bilateral orcontralateral lymph nodes, none more than
6cm in greatest dimension.
N2a
Metastasis in a single ipsilateral lymph node, more
than 3cm but not more than 6cm in greatest
dimension.
N2b Metastasis in multiple ipsilateral lymph nodes, none
more than 6cm ingreatest dimension.
N2c Metastasis in bilateral or contralateral lymph nodes,
none more than 6cm in greatest dimension.
N3 Metastasis in a lymph node, more than 6cm in greatest
dimension.
From the AJCC 7th edition “Cutaneous Squamous Cell Carcinoma and
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Table 4: Distant metastasis (M).
M0 No distant metastasis
M1 Distant metastasis
From the AJCC 7th edition “Cutaneous Squamous Cell Carcinoma and
Other Cutaneous Carcinomas”.
prognosis to an SCC invading the small bones of the
hand or foot with one displaying perineural involvement
of the skull base [2, 39]. Similarly, under this system, a
neoplasm with bony extension into the hand or foot would
be assigned a higher classiﬁcation than one invading the
maxilla, mandible, temple, or orbit, a distinction that seems
largely inappropriate. In addition, as T4 neoplasms are
automatically classiﬁed as Stage IV, there is the potential
for patients to be given a signiﬁcantly worse prognosis,
and subsequently a more aggressive treatment regimen, than
their primary cancer may warrant. As advocated by Warner
and Cockerell, we feel that appendicular bone involvement
should be grouped with T3 lesions rather than T4 [2].
Although not a signiﬁcant issue, a potential drawback
of the new T stages as they currently stand is that only
cSCC arising on the head or neck is capable of receiving
T3 classiﬁcation. While this likely represents an attempt to
achieve greater congruence with the head and neck staging
protocol, it seems awkwardly restrictive, particularly for
guidelines pertaining to the entire external body surface.
6. Changes in Stratiﬁcation of
Lymph Node Status
The nodal (N) staging system has been completely revised
compared to previous editions. In the past, only the presence
or absence of nodal metastasis was recorded, leaving no way
to diﬀerentiate a patient with sentinel node involvement
versus a patient with bilateral multinodal disease [5, 39]. In
thenewguidelines,nodesize,numberofinvolvednodes,and
the presence of contralateral or bilateral node involvement
are all included to better stratify patients. The inclusion
of these variables is the result of signiﬁcant evidence that
prognosis decreases with advancing nodal burden [42].
Under the new guidelines (Table 3), metastasis to a single
node less than 3cm in greatest dimension is deﬁned as
N1. The N2 designation refers to either a single node 3–
6cm in size, or multinodal disease where no individual
node is greater than 6cm in size. Based on the speciﬁc
patternofnodalinvolvement,N2issubcategorizedintothree
separate groupings. Involvement of a single ipsilateral node
is categorized as N2a, metastasis to multiple ipsilateral nodes
as N2b, and involvement of contralateral or bilateral lymph
nodes as N2c. The N3 designation is reserved for any lymph
node greater than 6cm in greatest dimension, regardless of
number of nodes involved.
In general, the recommendations regarding the nodal
staging are largely beneﬁcial, with only minor issues worth
noting. Under the new staging criteria, there is no mech-
anism for recognizing ipsilateral progressive nodal disease
beyond the single and multinodal distinctions. Additionally,
although it is likely that spread to distant lymph node basins
is associated with a worse prognosis than regional nodal
involvement, there is no mechanism for assigning this risk
unless there is spread to the contralateral side of the body.
Including these factors within staging guidelines would lead
to greater patient stratiﬁcation and improve the accuracy of
tumor-speciﬁc prognosis, although we recognize that such
a system designed to apply to the whole body may be
cumbersome and diﬃcult to apply to clinical practice.
Two additional omissions from the N staging criteria
are extracapsular invasion and micrometastasis. The absence
of micrometastasis is not surprising as this feature has
only recently gained recognition in staging guidelines for
other anatomic sites and is not frequently associated with
SCC. The omission of extracapsular involvement is more
curious as there is a precedent for its inclusion in other
chapters. In particular the guidelines for the penis, vulva,
and head and neck all contain some provision for recog-
nizing extracapsular invasion [1]. Finally, similar to our
recommendations regarding T staging, we feel that full nodal
assessment is largely unnecessary for small superﬁcial cSCC
cured with initial biopsy and verrucous cSCC (as well as
being unnecessary for basal cell carcinomas and cutaneous
tumors that behave in a benign fashion) [2].
7.M StagingGuidelines
No changes were made to the distant metastasis designation
of the AJCC cutaneous SCC staging system (Table 4).
Importantly, there is no provision for classiﬁcation of lymph
node metastasis far removed from regional nodal basins
as distant metastasis. This is in contrast to head and neck
carcinomas, for which the AJCC deﬁnes mediastinal lymphJournal of Skin Cancer 7
Table 5: Anatomic stage/prognostic groups.
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3 N0 M0
T1 N1 M0
T2 N1 M0
T3 N1 M0
Stage IV T1 N2 M0
T2 N2 M0
T3 N2 M0
TA n y N 3 M 0
T4 N Any M0
T Any N Any M1
From the AJCC 7th edition “Cutaneous Squamous Cell Carcinoma and
Other Cutaneous Carcinomas”.
node involvement excluding level VII as distant metastases
[1]. With this in mind, it might have been better to classify
metastases to mediastinal and retroperitoneal lymph nodes
as M1 lesions [2], although we recognize that it may be
problematic to deﬁne speciﬁc nodal locations as distant
metastases for a staging protocol applied to the entire skin
surface.
8. AnatomicStage/Prognostic
GroupsDesignation
Given the changes to the T and N classiﬁcations, the staging
groups oﬀer reasonable stratiﬁcation of patients based on
prognosis (Table 5). Brieﬂy, T1 and T2 tumors are assigned
Stage I and Stage II, respectively, Stage III includes all T3 or
N1 tumors that do not meet criteria for Stage IV, and the
presence of any T4, N2-3, or M1 designation is required for
Stage IV classiﬁcation.
One potential oversight is that the improved patient
stratiﬁcation aﬀorded by the new N guidelines is largely lost
whenappliedtothestaginggroup,asanyneoplasmreceiving
an N2 or N3 designation is automatically assigned Stage IV.
In order to more clearly distinguish N2 and N3 lesions, it has
been suggested that separate IVa and IVb groupings could
be created [2]. However, we recognize that this may not be
a feasible solution, as T4 or M1 lesions are also classiﬁed as
Stage IV, irrespective of N status. As mentioned previously,
the inclusion of T4 tumors with the Stage IV grouping raises
further concerns regarding the current inclusion of invasion
of the appendicular skeleton within T4 criteria.
9. Conclusions
Designing a comprehensive set of staging guidelines that are
accurate, easily applied, and eﬃcient represents a tremen-
dous challenge, one to which there is likely no perfect
solution. To that end, we applaud the authors of the
seventh edition for creating a set of guidelines that, although
imperfect,representasigniﬁcantimprovementoverprevious
editions. In particular, the creation of guidelines oriented
speciﬁcally towards cutaneous squamous cell carcinoma
enhances the ability to accurately assess the prognosis
associated with these types of lesions. Furthermore, incor-
poration of high risk features into the new cSCC guidelines
helps better stratify patients and assess tumor-speciﬁc risk.
However, despite these eﬀorts, the guidelines still contain
a number of signiﬁcant limitations. In particular, several
recommendationsarelargelyimpractical.Speciﬁcally,wefeel
that it is neither economically feasible nor medically justiﬁed
to perform full clinicopathologic staging criteria on the
verrucous variant of cSCC and small superﬁcial SCC cured
with primary biopsy. Similarly, for cutaneous neoplasms
that rarely metastasize, such as basal cell carcinoma, full
staging is unnecessary and should be mentioned in the
staging guidelines as an exception. In other cases, although
relevant, full initial evaluation of high-risk features may
not be possible, as primary biopsies frequently involve
only a small portion of the primary tumor, precluding
accurate assessment. Moreover, Mohs surgeons will need
to alter their clinical practice and either routinely send a
debulking specimen for H&E processing, or begin assessing
for vertical depth of invasion. Other issues that need to
be addressed include the lack of clear or comprehensive
deﬁnitions pertaining to the anatomy of the lip and the
histologic designation of “poorly diﬀerentiated” and “undif-
ferentiated” neoplasms. Moreover, future additions should
include important high-risk factors including SCC arising
at sites of burns/scars/sinus tracts/chronic inﬂammation
and/orincertainotherhigh-riskanatomicsitesnotcurrently
included in the staging criteria, and the presence of recurrent
or previously treated disease. Additionally, the current
classiﬁcation of cSCC with appendicular involvement with
T4 lesions is largely inappropriate, and these lesions would
be more appropriately designated as T3 lesions. Addressing
these concerns in subsequent editions would go a long way
towardimprovingtheaccuracy,applicability,andpracticality
of these guidelines.
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